SIMPLYBOOK.ME
8.2.2021 19:31:11 CET | Business Wire | Press release
The SimplyBook.me appointment scheduling system, originally created as a solution for a popular tire workshop in Iceland, is now processing millions of Covid vaccination and Covid test bookings worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005729/en/
Early 2020, when the pandemic started to spread, the management and staff of SimplyBook.me worried how it might affect the company and its future with the core clients being smaller service businesses. The management team took the stand to use the company's reserve funds to keep all its qualified staff, even though the situation might drag on for months. At the same time, work began to evaluate if SimplyBook.me could find its place in the fight against the spread of the virus.
At this point, widespread Covid testing had not begun, and social distancing and masks were the order of the day. The team immediately identified opportunities to help with organising social distancing as well as Covid testing. Despite the bombardment of cancellation requests from smaller service businesses using the software that experienced lockdowns and inability to function, the COVID-related services continued to grow stronger.
NHS in the UK approached SimplyBook.me during the summer of 2020 as they needed a booking solution to help them organise Covid testing in one of their areas. We jumped on the opportunity and fine-tuned our software to customise to their needs. The results spoke for themselves, and more and more NHS trusts joined up to use the software. When it became apparent that the UK was going to be the first to start vaccinating, SimplyBook.me put the full force of their development and support teams on setting up the software so it would work for vaccinations in the best way possible.
"The project leader and team we've been working with at the NHS, are outstanding in their work and organisation. I sincerely hope the UK administration understands the quality of all the people working behind the scenes so that everything works as planned. They are incredibly professional and demand nothing less than perfection" said Ingvar Gudmundsson founder and VP-Sales at SimplyBook.me. "It is a privilege to work with such dedicated people who are doing their utmost to deliver the best."
"It is now early 2021, and we are proud to have taken a direct part in the fight against the virus throughout the past ten months. The cherry on the top is knowing that we are now being used for vaccination scheduling, processing millions of bookings in only the first few weeks since it started. We were always confident that we had built a great flexible software, adaptable to be used in all sorts of situations. This original vision has helped us grow faster than ever, keep all staff fully employed, and finally be at the forefront in the fight against the biggest plague of the last century."
________________________________________________________________________
SimplyBook.me is one of the world's top booking systems – a 360-degree software service which acts as a growth tool for SMEs, health organisations and educational institutions. The SimplyBook.me mission is bringing people and service businesses together by enabling them to easily book their services online no matter where, when or which.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005729/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom